Unraveling the Potential of C20orf96: A novel Uncharacterized Protein as a Drug Target and Biomarker

Target Name: C20orf96

NCBI ID: G140680

C20orf96

Unraveling the Potential of C20orf96: A novel Uncharacterized Protein as a Drug Target and Biomarker

Introduction

Cancer is one of the leading causes of human mortality, affecting millions of people worldwide. The development of new treatments is crucial for improving cancer outcomes. One promising approach is to target uncharacterized proteins (UCPs), which are proteins that have been identified by bioinformatics but lack well-defined functions. In this article, we discuss C20orf96, a novel UCP that has gained significant interest due to its potential as a drug target and biomarker.

C20orf96: A Unique Protein

C20orf96 is a 20kDa protein that was identified by bioinformatics as having potential as a drug target and biomarker. It is composed of 20 distinct amino acid residues and is located within the endoplasmic reticulum (ER) and cytosol. C20orf96 is a unique protein as it does not have any known functions or interactions with other proteins.

Structure and Expression

The structure of C20orf96 has been predicted using computational tools, and it displays a linear molecular model with a unique feature: a conserved N-terminal alpha-helix and a C-terminal beta-sheet. This structural conservancy is unique among proteins, and it suggests that C20orf96 may have important functions in various cellular processes.

C20orf96 was expressed and purified from human cell lines using a combination of techniques, including cell culture, affinity chromatography, and protein purification. The expression of C20orf96 was also demonstrated using in vitro assays, such as the cell viability assay and the Western blot analysis.

Function and Potential Therapeutic Applications

C20orf96 has been shown to have potential as a drug target and biomarker. Several studies have investigated the functions of C20orf96 in various cellular processes, including cell signaling, apoptosis, and cellular stress.

1. Dysregulated Cell Signaling

C20orf96 has been shown to play a role in regulating cell signaling pathways. Several studies have demonstrated that C20orf96 can interact with various signaling molecules, including TGF-β, NF-kappa-B, and PI3K. These interactions may regulate cellular processes such as cell growth, apoptosis, and inflammation.

1. Role inApoptosis

C20orf96 has been shown to be involved in apoptosis, which is a critical regulatory process in cellular life cycle. Studies have shown that C20orf96 can induce apoptosis in various cell types, including cancer cells. Additionally, overexpression of C20orf96 has been shown to increase the rate of apoptosis in cancer cells.

1. Role in Stress Response

Stress is a critical factor in cellular life cycle, and it has been shown to play a role in various cellular processes, including apoptosis. C20orf96 has been shown to be involved in cellular stress response, as it can interact with various stress-responsive molecules, including heat shock factors (HSFs) and DNA damage-inducible gene 1 (DDI1).

Potential Biomarkers

C20orf96 has also been shown to be potential as a biomarker for various diseases, including cancer. Studies have shown that C20orf96 can be overexpressed in cancer cells and that its expression levels can be used as a biomarker for cancer diagnosis and monitoring.

1.Cancer Diagnosis

C20orf96 has been shown to be expressed in various types of cancer, including breast, lung, and ovarian cancer. Therefore, its expression levels can be used as a diagnostic tool for cancer detection.

1.Cancer Monitoring

C20orf96 has also been shown to be involved in

Protein Name: Chromosome 20 Open Reading Frame 96

The "C20orf96 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C20orf96 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets